Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 51
Filtrar
2.
JAMA Dermatol ; 156(10): 1074-1078, 2020 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-32845288

RESUMO

Importance: Insurance companies use prior authorizations (PAs) to address inappropriate prescribing or unnecessary variations in care, most often for expensive medications. Prior authorizations negatively affect patient care and add costs and administrative burden to dermatology offices. Objective: To quantify the administrative burden and costs of dermatology PAs. Design, Setting, and Participants: The University of Utah Department of Dermatology employs 2 full-time and 8 part-time PA staff. In this cross-sectional study at a large academic department spanning 11 clinical locations, these staff itemized all PA-related encounters over a 30-day period in September 2016. Staff salary and benefits were publicly available. Data were analyzed between December 2018 and August 2019. Main Outcomes and Measures: Proportion of visits requiring PAs, median administrative time to finalize a PA (either approval or denial after appeal), and median cost per PA type. Results: In September 2016, 626 PAs were generated from 9512 patient encounters. Staff spent 169.7 hours directly handling PAs, costing a median of $6.72 per PA. Biologic PAs cost a median of $15.80 each and took as long as 31 business days to complete. The costliest PA equaled 106% of the associated visit's Medicare reimbursement rate. Approval rates were 99.6% for procedures, 78.9% for biologics, and 58.2% for other medications. After appeal, 5 of 23 (21.7%) previously denied PAs were subsequently approved. Conclusions and Relevance: Prior authorizations are costly to dermatology practices and their value appears limited for some requests. Fewer unnecessary PAs and appeals might increase practice efficiency and improve patient outcomes.


Assuntos
Dermatologia/economia , Eficiência Organizacional/economia , Autorização Prévia/economia , Dermatopatias/terapia , Estudos Transversais , Fármacos Dermatológicos/economia , Fármacos Dermatológicos/uso terapêutico , Dermatologia/organização & administração , Dermatologia/estatística & dados numéricos , Prescrições de Medicamentos/economia , Prescrições de Medicamentos/estatística & dados numéricos , Eficiência Organizacional/estatística & dados numéricos , Hospitais Universitários/economia , Hospitais Universitários/organização & administração , Hospitais Universitários/estatística & dados numéricos , Humanos , Medicare/economia , Medicare/estatística & dados numéricos , Cirurgia de Mohs/economia , Cirurgia de Mohs/estatística & dados numéricos , Autorização Prévia/estatística & dados numéricos , Mecanismo de Reembolso/economia , Mecanismo de Reembolso/estatística & dados numéricos , Dermatopatias/sangue , Dermatopatias/economia , Fatores de Tempo , Terapia Ultravioleta/economia , Terapia Ultravioleta/estatística & dados numéricos , Estados Unidos
5.
Dermatology ; 234(5-6): 166-172, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30205372

RESUMO

BACKGROUND: The prevalence of narrow-band ultraviolet B (NB-UVB) use in Europe for moderate and severe psoriasis is unknown, because national registries for psoriasis do not monitor this treatment. OBJECTIVES: To quantify the use of phototherapy, biologics or conventional treatments in psoriasis, in a setting where European Medicines Agency (EMA) eligibility criteria for biologics were strictly applied, and phototherapy was included among first-line treatments. METHODS: We followed a cohort of 1,090 patients who were referred to the only centre entitled to prescribe biologics and phototherapy during a 5-year period. RESULTS: The cumulative number of treatment cycles was: 1,047 with NB-UVB phototherapy, 650 with systemic treatments and 239 with biologics; 754 patients received at least 1 course of NB-UVB phototherapy, 422 at least 1 course with a systemic treatment and 137 with a biologic; 595 patients were treated only with phototherapy. CONCLUSIONS: Regular use of NB-UVB as first-line treatment for moderate and severe psoriasis and adherence to the EMA eligibility criteria for biologics led to a relatively restricted use of biologics.


Assuntos
Produtos Biológicos/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Psoríase/tratamento farmacológico , Psoríase/radioterapia , Terapia Ultravioleta/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Europa (Continente) , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Adulto Jovem
6.
Rev. méd. Minas Gerais ; 28: [1-5], jan.-dez. 2018.
Artigo em Português | LILACS | ID: biblio-970385

RESUMO

Micose fungoide é uma neoplasia dos linfócitos T helper que afeta a pele e geralmente não apresenta manifestações extracutâneas por muitos anos. Já a micose fungoide hipocromiante (MFH) corresponde a um subtipo daquela com melhor prognóstico e que se apresenta com lesões hipocrômicas a acrômicas, com distribuição mais comum em tronco, regiões proximais de extremidades e cintura pélvica. O diagnóstico é firmado pela apresentação clínica aliada à histopatologia, que evidencia epidermotropismo com linfócitos atípicos. A doença geralmente apresenta boa resposta ao tratamento, o qual pode ser realizado com fototerapia com raios ultravioleta A (UVA), ultravioleta B (UVB), mostarda nitrogenada tópica, carmustina tópica e irradiação cutânea com elétrons. Descreve-se o caso de uma criança com máculas hipocrômicas que surgiram inicialmente no abdome, posteriormente se estendendo para raiz de coxas e região inguinal. As lesões apresentavam descamação fina, porém sem eritema ou prurido e ausência de linfonodomegalia palpável. A princípio o caso foi conduzido como eczemátide hipocromiante, mas o paciente apresentou agravamento importante das lesões em poucos meses apesar do tratamento, sendo assim, aventada a hipótese diagnóstica de MFH. Duas biópsias de pele foram realizadas, e os exames anatomopatológico e imunohistoquímica evidenciaram certo epidermotropismo, mas sem atipia de linfócitos. Foi orientado helioterapia domiciliar, com exposição corporal de 10 minutos no período da manhã, além do uso de emolientes e cuidados gerais com a pele, com relativa boa resposta. O acompanhamento é semestral e caso haja modificação do quadro, a biópsia com estudo histopatológico e a imunohistoquímica serão realizados novamente. (AU)


Mycosis fungoides is a type of cancer of the T helper lymphocytes that affects the skin and generally has no extracutaneous manifestations for many years. Otherwise, hypopigmented mycosis fungoides corresponds to a subtype with better prognosis and presents as hypopigmented or achromatic lesions, with more widespread distribution in the trunk, proximal parts of extremities and pelvic girdle. The diagnosis is confirmed by clinical presentation and histopathology, which shows epidermotropism and atypical lymphocytes. The disease usually show good response to treatment, which is performed with phototherapy with ultraviolet A (UVA), ultraviolet B (UVB), topical nitrogen mustard, topical carmustine and cutaneous irradiation with electrons. We describe the case of a child with hypochromic taint that initially appeared in the abdomen, later extending to root thighs and groin. The lesions had fine scaling, absence of erythema or itching, without the presence of palpable lymph node enlargement. At first the case was conducted as pytiriasis alba, but the patient had significant aggravation of injuries in a few months in spite of the treatment, thus mooted diagnosis of hypopigmented mycosis fungoides. Two skin biopsies were performed, and the histological and immunohistochemical tests showed epidermotropism but no atypia of lymphocytes. It was guided home heliotherapy, with body exposure of 10 minutes in the morning, besides the use of emollients and general skin care, with a relatively good response. The follow-up is bi-annually and if there is a modification in the condition, the biopsy with histopathological study and immunohistochemistry will be performed again. (AU)


Assuntos
Humanos , Terapia Ultravioleta/estatística & dados numéricos , Micose Fungoide/radioterapia , Linfoma , Anormalidades da Pele/terapia , Micose Fungoide/tratamento farmacológico , Terapêutica/métodos , Criança
8.
J Dermatol ; 45(3): 293-301, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29115687

RESUMO

Since 1982, the Japanese Society for Psoriasis Research has conducted annual epidemiological surveys of patients with psoriasis. Kawada et al. have reported data for 1982-2001 and Takahashi et al. have reported data for 2002-2008. The present study evaluated 9290 psoriatic cases according to age and sex (2009-2012). The male : female ratio was 2.08:1 (6281 male patients [67.6%] to 3009 female patients [32.4%]). The most prevalent type was psoriasis vulgaris (85.6% of all cases), which was followed by psoriasis arthropathica (6.0%), psoriasis guttate acuta (3.2%), Zumbusch-type generalized pustular psoriasis (1.8%) and psoriasis erythroderma (1.5%). Psoriasis vulgaris was the most prevalent type for all ages, while psoriasis arthropathica and psoriasis guttate acuta were most prevalent among patients aged less than 65 years. The present survey detected an increased number of cases with comorbid diabetes and/or arthritis symptoms compared with the previous surveys. We found that treatments frequently involved topical corticosteroids (89.7% of cases) and vitamin D3 ointments (78.0% of cases), with a notable increase in the use of vitamin D3 ointments. Systemic treatments were used in 33.3% of cases, including cyclosporin (33.6%), etretinate (19.5%), methotrexate (8.6%), infliximab (11.4%), adalimumab (10.9%) and ustekinumab (6.2%). Phototherapy was used in 30.9% of cases. Although psoralen plus ultraviolet A therapy was the predominant phototherapy during previous studies, the present survey revealed that narrowband ultraviolet B therapy was used in 84.5% of phototherapy-treated cases. Thus, the present survey revealed major changes in treatment trends.


Assuntos
Artrite/epidemiologia , Diabetes Mellitus/epidemiologia , Inquéritos Epidemiológicos/estatística & dados numéricos , Psoríase/epidemiologia , Adolescente , Adulto , Fatores Etários , Idade de Início , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Comorbidade , Fármacos Dermatológicos/uso terapêutico , Feminino , Humanos , Lactente , Recém-Nascido , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Psoríase/complicações , Psoríase/terapia , Índice de Gravidade de Doença , Fatores Sexuais , Terapia Ultravioleta/métodos , Terapia Ultravioleta/estatística & dados numéricos , Terapia Ultravioleta/tendências , Adulto Jovem
9.
J Dermatol ; 45(3): 314-317, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29047148

RESUMO

A local epidemiological survey of psoriasis was conducted from 19 February to 30 June 2016 in Matsumoto city, Nagano Prefecture, Japan. Patients were predominantly male (268 cases, 71.5% males vs 107 cases, 28.5% females). We estimated that the prevalence of psoriasis was 0.097% in the Matsumoto area. The clinical types of psoriasis identified were psoriasis vulgaris (90.7%), psoriatic arthritis (5.9%), pustular psoriasis (2.1%), guttate psoriasis (1.0%) and psoriatic erythroderma (0.3%). The topical therapeutic agents included corticosteroids (84.0%), vitamin D3 analogs (61.5%), and a combination of calcipotriol and betamethasone dipropionate (31.0%). Current systemic treatments included cyclosporin (9.0%), etretinate (7.4%) and methotrexate (1.3%). Biologic treatments included adalimumab (4.0%), ustekinumab (2.7%), infliximab (1.3%) and secukinumab (0.8%). Ultraviolet B therapy (11.3%) was the predominant phototherapy in which narrow band ultraviolet B therapy accounted for the majority, followed by psoralen and ultraviolet A therapy (1.0%). According to the recent evolution of psoriasis treatment, the use of biologics has been increasing. This study demonstrates the changes of treatment trends of psoriasis in a non-metropolitan regional area.


Assuntos
Produtos Biológicos/uso terapêutico , Inquéritos Epidemiológicos/estatística & dados numéricos , Psoríase/epidemiologia , Terapia Ultravioleta/métodos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Feminino , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Prevalência , Psoríase/terapia , Terapia Ultravioleta/estatística & dados numéricos , Adulto Jovem
10.
J Dtsch Dermatol Ges ; 15(2): 180-186, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28214304

RESUMO

BACKGROUND: While treatment of patients with moderate-to-severe psoriasis using a combination of fumaric acid esters (FAE, Fumaderm® ) and phototherapy (UV) is common practice, there have been hardly any studies investigating this regimen. Available information is limited to data from a small pilot study. The objective of the present study was to evaluate FAE/UV combination therapy in a larger patient cohort with moderate-to-severe psoriasis. PATIENTS AND METHODS: In this prospective noninterventional multicenter study, data from patients treated with FAE/UV combination therapy was assessed with regard to efficacy (PGA' PASI, DLQI, EQ-5D), safety, and dosage over a twelve-month period. The findings were subsequently compared to data from a previous retrospective study on FAE monotherapy. RESULTS: Data from 363 patients was included in the analysis. Efficacy measures improved substantially on combination therapy. Compared to FAE monotherapy, FAE/UV therapy led to a faster clinical response, however, there was no difference in efficacy after 12 months. Neither the duration nor the type of phototherapy had an impact on efficacy. In general, combination therapy was well tolerated. Seven percent of patients experienced adverse events. CONCLUSIONS: FAE/UV combination therapy is effective and well tolerated in patients with moderate-to-severe psoriasis. Such treatment may induce a faster therapeutic response, and appears to be useful, particularly in the first three months of FAE therapy.


Assuntos
Fumarato de Dimetilo/administração & dosagem , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Gastroenteropatias/epidemiologia , Psoríase/epidemiologia , Psoríase/terapia , Terapia Ultravioleta/estatística & dados numéricos , Adulto , Idoso , Idoso de 80 Anos ou mais , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/efeitos adversos , Terapia Combinada/efeitos adversos , Terapia Combinada/estatística & dados numéricos , Fármacos Dermatológicos/administração & dosagem , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico , Feminino , Gastroenteropatias/diagnóstico , Alemanha/epidemiologia , Humanos , Imunossupressores/administração & dosagem , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Prevalência , Psoríase/patologia , Resultado do Tratamento , Adulto Jovem
11.
J Am Acad Dermatol ; 72(6): 1078-80, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25981004

RESUMO

Of the wide range of treatment modalities available to dermatologists, few possess the history, efficacy, and safety of phototherapy. It should be emphasized that dermatologists are the only group of physicians optimally trained and qualified to understand the medical indications of phototherapy. Phototherapy, recognized for its cost-effectiveness, should remain a consideration in patient treatment. Continued training and education in residency and thereafter is needed to maintain the proficiency of physicians. In addition, payors need continued education to ensure that insurance coverage of phototherapy is not a barrier for patients to access this therapy. To further improve and optimize the outcome, phototherapy research needs to be supported.


Assuntos
Fatores Biológicos/economia , Fototerapia/economia , Fototerapia/estatística & dados numéricos , Dermatopatias/patologia , Dermatopatias/terapia , Fatores Biológicos/uso terapêutico , Análise Custo-Benefício , Dermatologia/normas , Dermatologia/tendências , Feminino , Humanos , Incidência , Masculino , Terapia PUVA/economia , Terapia PUVA/métodos , Terapia PUVA/estatística & dados numéricos , Fototerapia/métodos , Psoríase/economia , Psoríase/terapia , Medição de Risco , Dermatopatias/economia , Resultado do Tratamento , Terapia Ultravioleta/economia , Terapia Ultravioleta/métodos , Terapia Ultravioleta/estatística & dados numéricos
14.
J Dtsch Dermatol Ges ; 12(1): 48-57, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24393314

RESUMO

BACKGROUND: The German psoriasis registry PsoBest records the long-term efficacy, safety, patient benefit and treatment regimens of psoriasis. PATIENTS AND METHODS: Patients with moderate or severe psoriasis are included in PsoBest when treatment with a conventional systemic agent or biologic is started for the first time. Observation time is five years. Standardized physician and patient case report forms are obtained every three to six months. Baseline data of patients included by 31 December 2012 are presented and compared to the national health care study PsoHealth 2007 (n = 2,009). RESULTS: 602 dermatology practices and clinics have been registered and 199 have recruited n = 2,556 patients (63 % by practices, 37 % by clinics). Initially, n = 808 received biologics (316 adalimumab, 34 efalizumab, 209 etanercept, 75 infliximab, 22 golimumab, 152 ustekinumab) and n = 1,651 conventional systemic therapy (928 fumaric acid esters, 518 methotrexate, 161 cyclosporine A, 191 other drugs or UV treatment). Compared to PsoHealth, patients in PsoBest had on average a higher disease severity (PASI 14.7 vs. 10.1; DLQI 11.0 vs. 7.5; EQ-5D VAS 54.0 vs. 64.5), shorter disease duration (18.2 vs. 21.3 yrs.), lower age (47.3 vs. 51.5), higher rates of psoriatic arthritis (20.5 vs. 19.1 %) and nail psoriasis (55.0 vs. 35.6 %). On average patients receiving biologics were younger, more often male and had higher disease severity and comorbidity. CONCLUSIONS: Patients in PsoBest represent patients with a high burden of disease.


Assuntos
Antineoplásicos/uso terapêutico , Padrões de Prática Médica/estatística & dados numéricos , Psoríase/epidemiologia , Psoríase/terapia , Sistema de Registros , Terapia Ultravioleta/estatística & dados numéricos , Adolescente , Adulto , Distribuição por Idade , Idoso , Produtos Biológicos/uso terapêutico , Dermatologia/estatística & dados numéricos , Feminino , Alemanha/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Fatores de Risco , Distribuição por Sexo , Resultado do Tratamento , Adulto Jovem
16.
Ophthalmologe ; 110(7): 639-44, 2013 Jul.
Artigo em Alemão | MEDLINE | ID: mdl-23760422

RESUMO

BACKGROUND: More than 10 years after the clinical introduction of corneal cross-linking (CXL) the indications and contraindications are still not yet defined. Fundamental for such a list is the incidence of complications. METHODS: A PubMed search for complications of corneal crosslinking published up to March 2013 was carried out. RESULTS: The published complication rates ranged from 1 % to 10 % depending on the stage of keratoconus. Early postoperative complications were transient stromal haze, sterile infiltrates, endothelium decompensation, delayed epithelial healing and infectious keratitis. Stromal opacity can be a delayed postoperative event. CONCLUSIONS: Complications after corneal cross-linking treatment for keratoconus are rare but the management of these complications may need keratoplasty.


Assuntos
Ceratite/epidemiologia , Ceratite/prevenção & controle , Ceratocone/epidemiologia , Ceratocone/cirurgia , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/prevenção & controle , Terapia Ultravioleta/estatística & dados numéricos , Comorbidade , Humanos , Incidência , Fármacos Fotossensibilizantes/uso terapêutico , Fatores de Risco
17.
An Bras Dermatol ; 88(2): 211-5, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23739698

RESUMO

BACKGROUND: Phototherapy consists of exposure to ultraviolet radiation for therapeutic reasons. Radiation is already used in dermatological practice, and many studies have already proved the beneficial effect of UV light treatment for chronic inflammatory or lymphoproliferative skin diseases. The Dermatology Service of the Clinics Hospital of Porto Alegre (Hospital de Clínicas de Porto Alegre) has been using phototherapy for a long time, and no official data have been described so far. OBJECTIVES: To study the prevalence of dermatoses referred to the phototherapy unit at the Clinics Hospital of Porto Alegre and describe the total number of patients who have already been referred to this sector and their phototype. METHODS: This is a descriptive cross-sectional study. Data were collected through a review of the phototherapy patients' records (secondary data), which are available on a database of the Dermatology Service of the Clinics Hospital of Porto Alegre, from August 1997 to July 2011. RESULTS: A total of 653 records were analyzed. Phototype 3 was the most prevalent (n=313). Distribution of the prevalence of dermatoses referred to the phototherapy unit was as follows: vitiligo (279), psoriasis (255), cutaneous T-cell lymphoma/mycosis fungoides (29), graftversus-host disease (15), scleroderma (11), atopic dermatitis (10), alopecia areata (6), parapsoriasis (5), eczema (4), granuloma annulare (4), and others (35). As vitiligo and psoriasis were the two most prevalent dermatoses, they were analyzed separately, with no statistical difference in prevalence between them (P=0,177). CONCLUSIONS: Our findings are in accordance with the literature, showing that although phototherapy is still mostly indicated to treat psoriasis, it has been used to treat other dermatoses, since the results are promising.


Assuntos
Dermatopatias/epidemiologia , Dermatopatias/radioterapia , Terapia Ultravioleta/estatística & dados numéricos , Brasil/epidemiologia , Estudos Transversais , Feminino , Humanos , Masculino , Prevalência , Distribuição por Sexo
18.
An. bras. dermatol ; 88(2): 211-215, abr. 2013. graf
Artigo em Inglês | LILACS | ID: lil-674173

RESUMO

BACKGROUND: Phototherapy consists of exposure to ultraviolet radiation for therapeutic reasons. Radiation is already used in dermatological practice, and many studies have already proved the beneficial effect of UV light treatment for chronic inflammatory or lymphoproliferative skin diseases. The Dermatology Service of the Clinics Hospital of Porto Alegre (Hospital de Clínicas de Porto Alegre) has been using phototherapy for a long time, and no official data have been described so far. OBJECTIVES: To study the prevalence of dermatoses referred to the phototherapy unit at the Clinics Hospital of Porto Alegre and describe the total number of patients who have already been referred to this sector and their phototype. METHODS: This is a descriptive cross-sectional study. Data were collected through a review of the phototherapy patients' records (secondary data), which are available on a database of the Dermatology Service of the Clinics Hospital of Porto Alegre, from August 1997 to July 2011. RESULTS: A total of 653 records were analyzed. Phototype 3 was the most prevalent (n=313). Distribution of the prevalence of dermatoses referred to the phototherapy unit was as follows: vitiligo (279), psoriasis (255), cutaneous T-cell lymphoma/mycosis fungoides (29), graftversus-host disease (15), scleroderma (11), atopic dermatitis (10), alopecia areata (6), parapsoriasis (5), eczema (4), granuloma annulare (4), and others (35). As vitiligo and psoriasis were the two most prevalent dermatoses, they were analyzed separately, with no statistical difference in prevalence between them (P=0,177). CONCLUSIONS: Our findings are in accordance with the literature, showing that although phototherapy is still mostly indicated to treat psoriasis, it ...


FUNDAMENTOS: Fototerapia é exposição à radiação ultravioleta para uso terapêutico. O uso dessas radiações já é utilizado na prática dermatológica, e estudos já provaram o efeito benéfico do tratamento UV em doenças inflamatórias crônicas ou linfoproliferativas. O Serviço de Dermatologia do Hospital de Clínicas de Porto Alegre tem disponibilizado a fototerapia para seus pacientes há um longo tempo, sem dados oficiais descritos até então. OBJETIVO: Estudar a prevalência das dermatoses encaminhadas à fototerapia do Hospital de Clínicas de Porto Alegre e descrever o número total de pacientes já encaminhados a esse setor e seu fototipo. MÉTODOS: Estudo transversal descritivo. A coleta de dados foi feita por revisão da totalidade das fichas de cadastro dos pacientes de fototerapia (dados secundários), as quais se encontram em um banco de dados no Serviço de Dermatologia do Hospital de Clínicas de Porto Alegre, de agosto de 1997 a julho de 2011. RESULTADOS: Ao todo 653 pacientes foram analisados. O fototipo 3 foi o mais prevalente (n=313). A distribuição da prevalência das dermatoses foi: vitiligo (279), psoríase (255), linfoma cutâneo de células T/ micose fungóide (29), doença do enxerto versus hospedeiro (15), esclerodermia (11), dermatite atópica (10), alopécia areata (6), parapsoríase (5), eczema (4), granuloma anular (4) e outros (35). Visto que vitiligo e psoríase foram as dermatoses mais prevalentes, eles foram analisados separadamente. Não houve diferença estatística entre as prevalências ...


Assuntos
Feminino , Humanos , Masculino , Dermatopatias/epidemiologia , Dermatopatias/radioterapia , Terapia Ultravioleta/estatística & dados numéricos , Brasil/epidemiologia , Estudos Transversais , Prevalência , Distribuição por Sexo
19.
Rev. ANACEM (Impresa) ; 4(2): 73-75, dic. 2010. tab
Artigo em Espanhol | LILACS | ID: lil-618833

RESUMO

La psoriasis es un trastorno crónico común de la piel, se caracteriza por pápulas eritematosas y escamas blancas, aunque el diagnóstico diferencial de la psoriasis es amplio, en la gran mayoría de los casos sólo se necesita la anamnesis y el examen físico. En el tratamiento, la luz ultravioleta (UV) ha sido reconocida como beneficiosa a través de sus efectos antiproliferativos y anti- inflamatorios. El propósito nuestro trabajo es describir las características clínicas y epidemiológicas de esta patología en pacientes sometidos a fototerapia en el Hospital Hernán Henríquez Aravena de Temuco entre septiembre de 2007 y diciembre 2009.Se realizó un estudio retrospectivo en el que se revisaron fichas clínicas y informes de fototerapia de 60 pacientes portadores de psoriasis. El tipo clínico más común fue la psoriasis en placa con un 90 por ciento de los casos, seguida de psoriasis eritrodérmica con un 5 por ciento, el tipo de piel más común fue el Tipo 2 con un 87,7 por ciento de los casos. En cuanto a la severidad, la psoriasis moderada fue el 46,8 por ciento de los casos, con un índice de severidad y área de psoriasis (PASI) promedio del grupo estudiado de 11,61 siendo el tipo de psoriasis con mayor gravedad el tipo eritrodérmica (p=0,008). La asociación entre severidad y tipo de piel fue significativa siendo los tipos de piel 1 el que presentó mayor severidad (p=0,012). Nuestro estudio demostró algunas asociaciones significativas entre severidad y tipo de psoriasis, y con tipo de piel. Además de una frecuencia similar en ambos sexos coincidiendo con lo reportado en la literatura.


Psoriasis is a common chronic disorder of the skin which is generally characterized by red papules and white scales. Differential diagnosis of Psoriasis is wide, but it is possible to reach a proper diagnosis with the clinical history and physical examination. For the treatment Ultraviolet light (UV) has been recognized as beneficial, through both antoproliferative and antiinflamatory effects. The purpose of our work is to describe the clinical and epidemiologic features of this pathology in patients with diagnosis of psoriasis submitted for phototherapy in Hospital Hernan Henríquez Aravena of Temuco, between September 2007 and December 2009. A retrospective study was conducted in which there were review medical records and phototherapy protocols of 60 patients with diagnosis of psoriasis. The most common clinical type was the Plaque Psoriasis with 90 percent of the cases, followed by Erythrodermic Psoriasis with 5 percent. The most common skin type was type 2 with 87.7 percent of the cases. Regarding severity, moderate psoriasis presented in 46.8 percent of the cases, with an average Psoriasis area ans severity index (PASI) score of the studied group of 11.61, the type of mayor severity was the Erythrodermic psoriasis (p=0,008). The association between severity and type of skin was significant, being the patients with skin type 1 the ones that presented an increased disease severity (p = 0.012). Our study showed some significant associations between severity and type of psoriasis, and type of skin. Besides the similarity of frequence between genders coincides with previous literature reports.


Assuntos
Humanos , Masculino , Adolescente , Adulto , Feminino , Criança , Pessoa de Meia-Idade , Psoríase/epidemiologia , Psoríase/radioterapia , Terapia Ultravioleta/estatística & dados numéricos , Chile , Estudos Transversais , Psoríase/patologia , Psoríase/tratamento farmacológico , Índice de Gravidade de Doença , Terapia PUVA/estatística & dados numéricos
20.
Med Phys ; 37(10): 5251-7, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21089759

RESUMO

PURPOSE: Ultraviolet phototherapy is widely used in the treatment of numerous skin conditions. This treatment is well established and largely beneficial to patients on both physical and psychological levels; however, overexposure to ultraviolet radiation (UVR) can have detrimental effects, such as erythemal responses and ocular damage in addition to the potentially carcinogenic nature of UVR. For these reasons, it is essential to control and quantify the radiation dose incident upon the patient to ensure that it is both biologically effective and has the minimal possible impact on the surrounding unaffected tissue. METHODS: To date, there has been little work on dose modeling, and the output of artificial UVR sources is an area where research has been recommended. This work characterizes these sources by formalizing an approach from first principles and experimentally examining this model. RESULTS: An implementation of a line source model is found to give impressive accuracy and quantifies the output radiation well. CONCLUSIONS: This method could potentially serve as a basis for a full computational dose model for quantifying patient dose.


Assuntos
Terapia Ultravioleta/estatística & dados numéricos , Fenômenos Biofísicos , Humanos , Modelos Estatísticos , Dosagem Radioterapêutica , Pele/lesões , Pele/efeitos da radiação , Dermatopatias/terapia , Terapia Ultravioleta/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...